Completed PHASE3 INTERVENTIONAL NCT00727129

Study to Evaluate Divigel for the Treatment of Postmenoupausal Symptoms

Placebo-Controlled, Randomized, Double-Blind, Multicenter Study, to Demonstrate the Efficacy of 12 Weeks of Treatment With USL-221 on Moderate to Severe Vasomotor Symptoms and Vulvar/Vaginal Atrophy in Postmenopausal Patients

Sponsor: Upsher-Smith Laboratories

Conditions Postmenopausal Symptoms

Interventions Divigel

Updated 5 times since 2017 Last updated: Sep 25, 2008 Started: Jul 31, 2004 Completion: Aug 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Postmenopausal Symptoms, this trial is completed. The trial is conducted by Upsher-Smith Laboratories and has accumulated 5 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jul 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Upsher-Smith Laboratories

Data source: Upsher-Smith Laboratories

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.